Related Experiment Video
Updated: Feb 4, 2026
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future
Piyush Mehta1, C Bothiraja2, Shivajirao Kadam3
1a Department of Quality Assurance Technique, Poona College of Pharmacy , Bharati Vidyapeeth (Deemed-to-be-University) , Pune , India.
Abstract:
Tuberculosis (TB) is a contagious and airborne infectious disease caused by the pathogen Mycobacterium tuberculosis (Mtb). In spite of substantial research efforts, continuous multiple high-dose drug therapy regularly for 4-7 months can impede patient quality of life. The pathology of TB and biology of pulmonary airways permits for a variety of drug delivery strategies and natural route of infection denotes a more logical remedial approach for treatment of TB. Pulmonary delivery is non-invasive, allow easy transcytosis in alveolar region, avoids first-pass metabolism and extensive vascularization facilitates delivery of therapeutic agents to infection site. It also potentially reduces the frequency with dose requirement and linked side effects. Dry powder is a most preferred inhalation option due to their greater physiochemical stability over liquid or suspension based formulations. Dry powder inhalers (DPIs) are easy to handle and appropriate for high-dose formulations. Moreover, the progress of disciplines such as nanotechnology, particle engineering, material science and molecular biology permits further expansion of treatment capability and efficiency. Thus, this article will focus on the role of novel DPIs systems for treatment of TB. This article also contains a dedicated section discussing about technical limitations and clinical challenges with help of strengths, weaknesses, opportunities and threats (SWOT) analysis. Additionally, it will also offer some basic background information for drug repurposing, formulation development and drug delivery systems.
Insights
Novel dry powder inhalers (DPIs) offer a promising pulmonary drug delivery strategy for tuberculosis (TB) treatment. This approach enhances therapeutic efficiency and patient quality of life by targeting infection sites directly.
Area of Science:
- Pulmonary Drug Delivery
- Infectious Disease Treatment
- Nanotechnology in Medicine
Background:
- Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), requires lengthy high-dose drug therapy impacting patient quality of life.
- Pulmonary drug delivery offers a non-invasive, efficient route for TB treatment, bypassing first-pass metabolism and reaching infection sites directly.
- Dry powder inhalers (DPIs) provide physiochemical stability and ease of handling, making them suitable for high-dose TB formulations.
Purpose of the Study:
- To explore the role of novel dry powder inhaler (DPI) systems in the treatment of tuberculosis (TB).
- To discuss the technical limitations and clinical challenges associated with DPIs for TB using SWOT analysis.
- To provide background on drug repurposing, formulation development, and drug delivery systems relevant to TB.
Main Methods:
- Review of current research on pulmonary drug delivery for TB.
- Analysis of DPI technology advancements, including nanotechnology and particle engineering.
- SWOT analysis of DPI systems for TB treatment.
Main Results:
- Novel DPI systems demonstrate potential for improved TB treatment efficacy and reduced side effects.
- Pulmonary delivery via DPIs offers advantages over traditional TB treatment regimens.
- Technical and clinical challenges for DPI implementation in TB therapy were identified.
Conclusions:
- Novel DPI systems represent a significant advancement in pulmonary drug delivery for tuberculosis.
- Addressing identified limitations and challenges is crucial for successful clinical translation.
- Further research in formulation development and drug repurposing can enhance DPI-based TB therapies.
Related Concept Videos
01:23Inhaled Medications
01:24Pulmonary Ventilation: Inhalation
Boyle's law becomes particularly pertinent when examining respiratory...
01:20Inhalational Anesthetics: Overview
01:30Dry Friction
To illustrate this concept, imagine a wooden crate resting on a rough, non-uniform horizontal surface. When an external force is applied to...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...